Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Fampridine-SR – Treatment for Multiple Sclerosis

Drug (Brand/Generic)

Fampridine-SR (4-aminopyridine)

Company/Licensee

Acorda Therapeutics

Therapy Class

Potassium channel blocker

Product Description

Selective neuronal potassium (K+) channel blocker

Current Indication

Treatment of MS

Market Sector

CNS

Development Status

Approved in US. Marketing authorisation application submitted in EU and new drug application submitted in Canada
Expand

Free download worth over $5000
Download our 2019 Technology, Media and Telecoms Predictions Report

Worth up to $5,850

In this report, we look at the 30 big tech themes for 2019, identifying winners and losers for each theme. This report will impact all industries helping:

  • CEOs/Senior Staff: in all industries understand the disruptive threats to their competitive landscape
  • Investors: Helps fund managers focus their time on the most interesting investment opportunities in global TM
Close
Close
Close

Go Top